Literature DB >> 34731621

Closed-state inactivation and pore-blocker modulation mechanisms of human CaV2.2.

Yanli Dong1, Yiwei Gao1, Shuai Xu2, Yuhang Wang3, Zhuoya Yu3, Yue Li3, Bin Li3, Tian Yuan2, Bei Yang3, Xuejun Cai Zhang3, Daohua Jiang4, Zhuo Huang5, Yan Zhao6.   

Abstract

N-type voltage-gated calcium (CaV) channels mediate Ca2+ influx at presynaptic terminals in response to action potentials and play vital roles in synaptogenesis, release of neurotransmitters, and nociceptive transmission. Here, we elucidate a cryo-electron microscopy (cryo-EM) structure of the human CaV2.2 complex in apo, ziconotide-bound, and two CaV2.2-specific pore blockers-bound states. The second voltage-sensing domain (VSD) is captured in a resting-state conformation, trapped by a phosphatidylinositol 4,5-bisphosphate (PIP2) molecule, which is distinct from the other three VSDs of CaV2.2, as well as activated VSDs observed in previous structures of CaV channels. This structure reveals the molecular basis for the unique inactivation process of CaV2.2 channels, in which the intracellular gate formed by S6 helices is closed and a W-helix from the domain II-III linker stabilizes closed-state inactivation. The structures of this inactivated, drug-bound complex lay a solid foundation for developing new state-dependent blockers for treatment of chronic pain.
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ca(V)2.2; N-type; channel blocker; closed-state inactivation; neurotransmitter release; presynapse; voltage-gated calcium channel; ziconotide

Mesh:

Substances:

Year:  2021        PMID: 34731621     DOI: 10.1016/j.celrep.2021.109931

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  6 in total

1.  A 4/8 Subtype α-Conotoxin Vt1.27 Inhibits N-Type Calcium Channels With Potent Anti-Allodynic Effect.

Authors:  Shuo Wang; Peter Bartels; Cong Zhao; Arsalan Yousuf; Zhuguo Liu; Shuo Yu; Anuja R Bony; Xiaoli Ma; Qin Dai; Ting Sun; Na Liu; Mengke Yang; Rilei Yu; Weihong Du; David J Adams; Qiuyun Dai
Journal:  Front Pharmacol       Date:  2022-04-29       Impact factor: 5.988

Review 2.  Antimicrobial Peptide Mimics for Clinical Use: Does Size Matter?

Authors:  Johan Svenson; Natalia Molchanova; Christina I Schroeder
Journal:  Front Immunol       Date:  2022-05-26       Impact factor: 8.786

3.  Structural basis for pore blockade of human voltage-gated calcium channel Cav1.3 by motion sickness drug cinnarizine.

Authors:  Xia Yao; Shuai Gao; Nieng Yan
Journal:  Cell Res       Date:  2022-04-27       Impact factor: 46.297

Review 4.  Druggability of Voltage-Gated Sodium Channels-Exploring Old and New Drug Receptor Sites.

Authors:  Goragot Wisedchaisri; Tamer M Gamal El-Din
Journal:  Front Pharmacol       Date:  2022-03-17       Impact factor: 5.810

5.  Structure, gating, and pharmacology of human CaV3.3 channel.

Authors:  Lingli He; Zhuoya Yu; Ze Geng; Zhuo Huang; Changjiang Zhang; Yanli Dong; Yiwei Gao; Yuhang Wang; Qihao Chen; Le Sun; Xinyue Ma; Bo Huang; Xiaoqun Wang; Yan Zhao
Journal:  Nat Commun       Date:  2022-04-19       Impact factor: 17.694

6.  Unwinding and spiral sliding of S4 and domain rotation of VSD during the electromechanical coupling in Nav1.7.

Authors:  Gaoxingyu Huang; Qiurong Wu; Zhangqiang Li; Xueqin Jin; Xiaoshuang Huang; Tong Wu; Xiaojing Pan; Nieng Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-25       Impact factor: 12.779

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.